trending Market Intelligence /marketintelligence/en/news-insights/trending/LyesKI6W3zkrr8eXm2tQwQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Achillion shareholders approve $930M Alexion merger

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Achillion shareholders approve $930M Alexion merger

Achillion Pharmaceuticals Inc.'s shareholders approved the company's $930 million merger agreement to be acquired by Boston-based Alexion Pharmaceuticals Inc.

Among the shareholders who voted, about 99% cast their vote in favor of the acquisition.

Under the agreement, Alexion agreed to pay $6.30 for every Blue Bell, Pa.-based Achillion share it acquires, in addition to further consideration in the form of nontradeable contingent value rights if Achillion meets certain clinical and regulatory milestones.

The companies plan to submit their filings under the Hart-Scott-Rodino Antitrust Improvements Act in January 2020.

Achillion expects the acquisition to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the act.